Introduction

Aprepitant is a new generation of NK1 receptor antagonist that can cross the blood-brain barrier and occupy neurokinin-1 in the brain with high selectivity and high affinity, thereby inhibiting chemotherapy-induced nausea and vomiting at the central level. Vomit. On the basis of effectively preventing and controlling nausea and vomiting caused by anti-tumor treatment, it greatly improves patient compliance and reduces treatment risks.
Since its launch, aprepitant injection has been listed as a first-line recommendation by domestic and foreign consensus guidelines in relevant fields: for the prevention of nausea and vomiting (CINV) induced by moderate/highly emetogenic chemotherapy and multi-day chemotherapy.

Aprepitant injection prepared by ATS

Preparation:
(1) Weigh Ganoderma spore oil, refined egg yolk lecithin and oleic acid, stir to dissolve, add aprepitant, and heat in a water bath to 70°C to serve as the drug-carrying oil phase;
(2) Weigh glycerin and add it to purified water, and heat the water bath to 70°C to serve as the water phase;
(3) Slowly add the oil phase to the water phase, maintain the temperature at 70°C, and shear at high speed for 10 minutes to obtain colostrum; (4) The prepared colostrum is homogenized by ultra-high pressure micro-jet and cooled by a chiller;

Result:
After homogenization, the particle size can reach nanometer level D90=137nm.